Looking into the future with bioresorbable vascular scaffolds

Expert Review of Cardiovascular Therapy

Volumn 11, Issue 10, 2013, Pages 1407-1416

  Costopoulos, Charis ^a,b,c   Naganuma, Toru ^a,b   Latib, Azeem ^a,b   Colombo, Antonio ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b EMO GVM CENTRO CUORE COLUMBUS   (Italy)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Bioresorbable stent; Bioresorbable vascular scaffold; Drug eluting stent; Stent thrombosis; Target lesion revascularization

Indexed keywords

EVEROLIMUS; PACLITAXEL; RAPAMYCIN;

CONTROLLED STUDY; CORONARY ARTERY; DRUG ELUTING STENT; HUMAN; METAL STENT; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; REVIEW; STENT; STENT THROMBOSIS; TREATMENT INDICATION;

ABSORBABLE IMPLANTS; ANIMALS; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; HUMANS; POLYMERS; PROSTHESIS DESIGN; TISSUE SCAFFOLDS;

EID: 84886614337     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2013.839200     Document Type: Review

References (31)

1. Konig A, Schiele TM, Rieber J et al. Influence of stent design and deployment technique on neointima formation and vascular remodeling. Z. Kardiol. 91 (Suppl. 3), 98-102 (2002).
2. Nakazawa G, Otsuka F, Nakano M et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. JACC 57, 1314-1322 (2011).
3. Virmani R, Guagliumi G, Farb A et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 109, 701-705 (2004).
4. Heublein B, Rohde R, Kaese V, Niemeyer M, Hartung W, Haverich A. Biocorrosion of magnesium alloys: A new principle in cardiovascular implant technology? Heart 89, 651-656 (2003).
5. Erbel R, Di Mario C, Bartunek J et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: A prospective, non-randomised multicentre trial. Lancet 369, 1869-1875 (2007).
6. Haude M. Progress with drug-eluting magnesium resorbing stents (BIOTRONIK dreams program): DREAMS 2-year results. Presented at: Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, 22-26 October 2012.
7. Waksman R. Lessons learned from preclinical studies of magnesium scaffolds (Biotronik's DREAMS program). Presented at: PCR focus group on bioresorbable vascular scaffolds. Rotterdam, NL, 8-9 March 2012.
8. Ormiston JA, Serruys PW, Regar E et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de novo coronary artery lesions (ABSORB): A prospective open label trial. Lancet 371, 899-907 (2008).
9. Tanimoto S, Bruining N, van Domburg RT et al. Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology. J. Am. Coll. Cardiol. 52, 1616-1620 (2008).
10. Serruys PW, Onuma Y, Dudek D et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J. Am. Coll. Cardiol. 58 (15), 1578-88 (2011).
11. Serruys PW, Ormiston JA, Onuma Y et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 373, 897-910 (2009).
12. Serruys PW, Onuma Y, on behalf of the ABSORB A & B investigators. ABSORB Cohort B: 6 m, 12 m, 18 m and 24 m follow-up. Presented at: PCR Focus Group on Bioresorbable Vascular Scaffolds. Rotterdam, NL, 8-9 March 2012.
13. Diletti R, Farooq V, Girasis C et al. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: Does bioresorption matter with small vessel size? Insight from the ABSORB cohort Btrial. Heart 99, 98-105, (2013)
14. Van Geuns R. BVS expand: First result of wide clinical applications of Bioresorbable Vascular Scaffold. Presented at: EuroPCR. Paris, FRA, 21-24 May 2013.
15. Dudek D, Rzeszutko A, Lekston A et al. Bioresorbable Vascular Scaffolds (BVS) in patients with acute coronary syndrome. The muticenter registry in Poland: POLAR ACS. Presented at: EuroPCR. Paris, FRA, 21-24 May 2013.
16. Widimsky P. Bioresorbable vascular scaffolds in acute STEMI: Prague-19 study. Presented at: EuroPCR. Paris, FRA, 21-24 May 2013.
17. Serruys PW. An interim report on the 12-month clinical outcomes from the first 450 patients registered. Presented at: EuroPCR. Paris, FRA, 21-24 May 2013.
18. Verheye S. DeSolve first in-man study preliminary results. Presented at: PCR Focus Group on Bioresorbable Vascular Scaffolds. Rotterdam, NL, 8-9 March 2012.
19. Verheye S, on behalf of the DESolve investigators. First-in-Man results with a Myolimus-Eluting bioresorbable PLLA-based vascular scaffold (Elixir DESolve). Presented at: Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, 22-26 October 2012.
20. Jabara R. Poly-Anhydride based on salicylic acid and adipic acid anhydride. Presented at: EuroPCR. Barcelona, SPN, 19-22 May 2009.
21. Jabara R. Bio-mechanical properties and ABC of bioresorption of adipic acid. Presented at: PCR Focus Group on Bioresorbable Vascular Scaffolds. Rotterdam, NL, 8-9 March 2012.
22. Grube E. Bioabsorbable stent. The Boston scientific and REVA technology. Presented at: EuroPCR. Barcelona, SPN, 19-22 May 2009.
23. Costa R. REVA ReZolve clinical program update. Presented at: Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, 22-26 October 2012.
24. Cottone RJ, Thatcher GL, Parker SP et al. OrbusNeich fully absorbable coronary stent platform incorporating dual partitioned coatings. EuroIntervention 5 (Suppl. F), F65-71 (2009).
25. Shen L, Wang Q, Wu Y, Xie J, Ge J. Short-Term effects of sirolimus eluting fully bioabsorbable polymeric coronary stents in a porcine model. Presented at: Transcatheter Cardiovascular Therapeutics (TCT) conference. San Francisco, CA, 7-11 November 2011.
26. Tamai H, Igaki K, Kyo E et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 102, 399-404 (2000).
27. Nishio S, Kosuga K, Igaki K et al. Long-Term (>10 years) clinical outcomes of first-in-man biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai Stents. Circulation 125, 2343-2353 (2012).
28. Lafont A. ART bioresorbable stent. Arterial remodeling in preclinical models. Presented at: PCR Focus Group On Bioresorbable Vascular Scaffolds. Rotterdam, NL, 8-9 March 2012.
29. Gomez-Lara J, Garcia-Garcia HM, Onuma Y et al. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc. Interv. 3, 1190-1198 (2010).
30. Palmerini T, Sangiorgi D, Marzocchi A et al. Ostial and midshaft lesions vs. bifurcation lesions in 1111 patients with unprotected left main coronary artery stenosis treated with drug-eluting stents: Results of the survey from the Italian Society of Invasive Cardiology. Eur. Heart J. 30, 2087-2094 (2009).
31. Ozaki Y, Okumura M, Ismail TF et al. The fate of incomplete stent apposition with drug-eluting stents: An optical coherence tomography-based natural history study. Eur. Heart J. 31, 1470-1476 (2010).